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Primary cardiomyopathies (CMPs) are monogenic but multi-allelic disorders with dozens
of genes involved in pathogenesis. The implementation of next-generation sequencing
(NGS) approaches has resulted in more time- and cost-efficient DNA diagnostics of
cardiomyopathies. However, the diagnostic yield of genetic testing for each subtype
of CMP fails to exceed 60%. The aim of this study was to demonstrate that allelic
dropout (ADO) is a common phenomenon that reduces the diagnostic yield in primary
cardiomyopathy genetic testing based on targeted gene panels assayed on the Ion
Torrent platform. We performed mutational screening with three custom targeted gene
panels based on sets of oligoprimers designed automatically using AmpliSeq Designer®
containing 1049 primer pairs for 37 genes with a total length of 153 kb. DNA samples
from 232 patients were screened with at least one of these targeted gene panels. We
detected six ADO events in both IonTorrent PGM (three cases) and capillary Sanger
sequencing (three cases) data, identifying ADO-causing variants in all cases. All ADO
events occurred due to common or rare single nucleotide variants (SNVs) in the
oligoprimer binding sites and were detected because of the presence of “marker” SNVs
in the target DNA fragment. We ultimately identified that PCR-based NGS involves a risk
of ADO that necessitates the use of Sanger sequencing to validate NGS results. We
assume that oligoprimer design without ADO data affects the amplification efficiency of
up to 0.77% of amplicons.
Keywords: allelic dropout, cardiomyopathy, next-generation sequencing, Sanger sequencing, diagnostic yield,
DNA diagnostics
INTRODUCTION
In recent years, the study of the genetic causes of monogenic diseases has evolved from a basic
science research area into widely accepted clinical testing protocols with substantial impacts
on diagnostics and clinical decision-making (Ackerman et al., 2011). Primary cardiomyopathies
(CMP) are monogenic but multi-allelic disorders with dozens of genes involved in pathogenesis
(Hershberger et al., 2018). The prevalence of clinically expressed and hypertrophic cardiomyopathy
(HCM) gene carriers has been greatly underestimated and could be as high as 1:200 (Semsarian
et al., 2015).
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The implementation of NGS approaches has resulted in more
time- and cost-efficient DNA diagnostics of cardiomyopathies.
However, the diagnostic yield of genetic testing for each subtype
of CMP fails to exceed 60% (Hershberger et al., 2018). Negative
results obtained by genetic testing do not rule out the presence
of genetic disease because our knowledge about the molecular
pathogenesis of disease is still evolving. Moreover, the technical
limitations of all known techniques of DNA/RNA analysis
and variant interpretation contribute to incomplete results.
Alternative sequencing approaches such as capillary Sanger
sequencing confirm the genetic variants found by NGS methods
to increase the reliability of the DNA test results (Baudhuin et al.,
2015).
Allelic dropout (ADO) is a common phenomenon that
reduces the efficiency of PCR-based targeted sequencing. It
was first described in 1991 as a “partial amplification failure,”
causing a potential source of misdiagnosis for both dominant
and recessive diseases (Navidi and Arnheim, 1991). The practical
importance of the ADO phenomenon was originally shown in
1997 by Lissens and Sermon in a case of preimplantation genetic
diagnosis of cystic fibrosis wherein the heterozygous 1F508
mutation in the CFTR gene was not detected in 25% of mutant
blastomeres (Lissens and Sermon, 1997). The ADO phenomenon
involves selective allele amplification during the polymerase
chain reaction (PCR) thermocycling process. The presence of
single nucleotide variants (SNVs) in the forward and/or reverse
oligoprimer binding sites may lead to the complete or partial lack
of amplification of the single allele, while the second one may
“drop” out during the PCR process. In such cases, SNVs causing
ADO are usually located closer to the 3′ end of the oligoprimer
binding site (Martins et al., 2011).
Bi-directional capillary Sanger sequencing and high-
throughput semiconductor sequencing approaches are routinely
used for cross-validation of genetic findings (Baudhuin et al.,
2015; Di Resta and Ferrari, 2018). Both approaches are PCR-
based, share similar limitations, and may be negatively impacted
by ADO. However, the incidence of ADO events in these
PCR-based diagnostic assays remains unknown.
The aim of this study was to demonstrate that ADO is
a common phenomenon influencing the diagnostic yield of
targeted gene panel testing of primary CMPs on the Ion Torrent
platform with follow-up verification by Sanger sequencing.
MATERIALS AND METHODS
We performed genetic testing on DNA samples from 232
patients diagnosed with inherited cardiomyopathies in clinical
centres. This study was performed in accordance with the
1964 Helsinki declaration, its later amendments and local ethics
committee. Written informed consent was obtained from all
individual participants included in the study. DNA samples were
extracted from venous blood using Quick-DNA Miniprep Plus
Kit (Zymo Research Corp., Irvine, CA, USA) according to the
manufacturer’s instructions.
Mutational screening was performed using three custom
targeted gene panels with two sets of oligoprimers designed
automatically using Ion AmpliSeq Designer® (Thermo Fisher
Scientific, Waltham, MA, USA) containing 1,049 primer pairs
for 37 genes, with a total length of 153 kb. More detailed
characteristics of each target genes panels are presented in
Supplementary Table 1. Manufacturer grouped primers for each
panel in 2 pools. Libraries preparation was performed using Ion
AmpliSeqTM Library Kit 2.0 according to the manufacturer’s
instructions (Thermo Fisher Scientific). Sequencing was
performed on Ion 314TM and Ion 316TM chips using high-
throughput semiconductor sequencing on an Ion PGMTM
System according to the manufacturer’s instructions (Thermo
Fisher Scientific). Average reads per amplicon were 192, mean
coverage with at least 20 reads−94.7%, mean coverage with
at least 100 reads−79.51%. Data from the Ion PGMTM System
were processed with CoverageAnalysis and VariantCaller plugins
available within licensed Torrent Suite Software 5.6.0 and Ion
Reporter Software (Thermo Fisher Scientific). NGS sequencing
reads were visualized using the Integrative Genomic Viewer
(IGV) tool (Robinson et al., 2011) using hg19 as a reference
genome. All DNA samples were screened with at least one of the
targeted gene panels mentioned.
Rare genetic variants detected by NGS were verified via
bi-directional capillary Sanger sequencing on an ABI 3730XL
DNA Analyzer according to the manufacturer’s instructions
(Thermo Fisher Scientific). Alternative pairs of oligoprimers
flanking the coding and adjacent intronic regions of the 37 genes
were designed for PCR using open-source PerlPrimer (Marshall,
2004). The PCR protocol and annealing temperature of the
primers were determined experimentally. The results of direct
Sanger sequencing were visualized using Chromas 2 software
(Technelysium Pty Ltd, South Brisbane, Australia).
All archival direct Sanger sequencing chromatograms were
involved in the study to track the ADO phenomenon.
Genetic variants found by NGS were visually compared with
Sanger sequencing chromatograms, noting the possible loss of
heterozygosity or underrepresentation of alternative alleles. To
reveal the cause of ADO, forward- and reverse-primer binding
sites were analysed using the Genome Aggregation Database
(gnomAD) (Karczewski et al., 2020). In order to exclude only
one allele amplification, all amplicons with noted or suspected
ADO cases were re-sequenced with alternative non-overlapping
oligoprimer pairs.
All genetic variants newly detected in this study were
registered in public database ClinVar (https://www.ncbi.nlm.
nih.gov/clinvar/). List of variants with accession numbers is
summarized in Supplementary Table 2.
RESULTS
We performed mutational screening on 232 DNA samples from
patients diagnosed with different types of inherited CMPs. The
DNA samples were screened with at least one of the three targeted
gene panels.
We found that three ADO cases occurred during sequencing
on the IonTorrent platform and three occurred during capillary
Sanger sequencing. In the targeted gene panels, ADO led
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to underrepresentation/loss of marker variants in NGS reads
(Table 1). The Sanger sequencing chromatograms revealed a
dropout of the allele due to the loss of heterozygosity of the
already detected (“marker”) SNV (Table 1). Control capillary re-
sequencing using additional alternative oligoprimers confirmed
the true allelic status.
We identified the cause of ADO in all six cases (Table 1). In
the targeted genes, ADO was caused by rare or unique genetic
variants in the oligoprimer binding sites; in capillary Sanger
sequencing, all ADO cases occurred due to common SNVs.
We found that the ADO phenomenon may lead not only to
the complete loss of an allele but also to the underrepresentation
of the “marker” variant in NGS reads. For example, the
heterozygous rare missense variant c.641G>A (p.R214Q) in the
SCN1B gene was detected in only 1 of 2 overlapping amplicons
by target IonTorrent sequencing and was represented in 5%
of all reads (Figure 1A). This caused the loss of two missense
variants, —c.744C>A (p.S248R) and c.749G>C (p.R250T)—and
only reads with the wild-type allele were displayed. The presence
of all three linked heterozygous missense variants—c.641G>A
(p.R214Q), c.744C>A (p.S248R), and c.749G>C (p.R250T)—in
the SCN1B gene in the DNA sample was confirmed by control
Sanger sequencing (Figure 1B).
To reproduce this case of ADO in a single (i.e., non-
multiplexed) PCR, we performed a single control PCR with two
oligoprimers designed by AmpliSeq and flanking genomic region
chr19:35524839-35525003 (the corresponding target region of
the SCN1B gene). This amplicon was sequenced separately by
capillary Sanger sequencing and the loss of the allele containing
the c.641G>A (p.R214Q) variant was reproduced (Figure 1C).
Cross-validation of DNA diagnostic results using an
alternative sequencing approach (capillary Sanger sequencing
was performed first as a basic method) allowed us to identify a
case of allelic dropout in the SCN5A gene in an Iranian family
with Brugada syndrome (Figure 2A). Heterozygous missense
variant c.4516C>T (p.P1506S) in exon 26 of the SCN5A gene
was found by capillary Sanger sequencing in DNA samples
of the proband (Figure 2B) and proband’s brother. However,
further cascade familial screening revealed this missense variant
in the proband’s nephew in the hemizygous state (Figure 2C).
Theoretically, the hemizygous state of this c.4516C>T variant
in the II-4 family member may involve alternative explanations
such as consanguinity in the family or de novo deletion of the
SCN5A gene in the maternal allele, but it did not fit the clinical
phenotype and family history. Dropout of the wild-type allele
was the most reliable explanation.
Manual analysis of oligoprimer binding sites using
gnomAD revealed the presence of a common genetic variant
c.4542+89C>T [total minor allele frequency (MAF) 0.098]
in the 3′-end of the R-primer which caused ADO. This
heterozygous SNV was detected in DNA samples of patient
II-4 and his mother by PCR-RFLP analysis using an additional
pair of oligoprimers flanking this region. Absence of genetic
variant c.4516C>T (p.P1506S) in the mother’s DNA sample
was confirmed by capillary Sanger sequencing with two
independent oligoprimers and PCR-RFLP analysis. Control
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FIGURE 1 | Allelic dropout in the SCN1B gene in DNA sample of proband NRF124. (A) Ion Torrent PGM sequencing results. Genetic variant c.641G>A is detected
on only one of two overlapping amplicons. (B) Fragment of the Sanger sequencing chromatogram showing the presence of heterozygous variant c.641G>A in the
proband (arrow). (C) Fragment of the Sanger sequencing chromatogram obtained with oligoprimers identical to AmpliSeq.
member II-4 is a carrier of heterozygous c.4516C>T (p.P1506S)
(Figure 2D).
In one case, we detected ADO when comparing results
from two consecutive targeted gene panel sequencing
assays with overlapping gene spectra and different
oligoprimers encompassing the target regions of the LDB3
gene. A variant of unknown significance—c.1051A>G
(p.T351A)—in the LDB3 gene in sample ARVD19 was
detected only by panel I (“Genes encoding desmosomal
and associated proteins”) (Supplementary Figure 1A)
but not in panel II (“Genes encoding sarcomeric and
associated proteins”) (Supplementary Figure 1B). This
SNV was also confirmed by control capillary sequencing
(Supplementary Figure 1C).
We also found that ADO may occur not only due to
localization of SNVs in the 3′-end of oligoprimer binding sites,
but also close to the 5′-end. Deep intronic variant c.2300-
195A>G in the PKP2 gene was located close to the 5′-end and
led to ADO in nine samples studied (Table 1).
We found that ADO is a non-consistent process even in the
same DNA sample. For example, three consecutive PCR capillary
sequencing runs with sample ARVD16 yielded one positive
result (heterozygous variant c.2091A>G was detected) and two
negative results (complete loss of the c.2091A>G variant). This
ADO event was caused by the intronic variant c.1904-49T>A
located at the 3′-end of the primer-binding site.
All amplicons with identified ADO events were carefully re-
sequenced using alternative oligoprimer pairs and selective allele
amplification was confirmed in all cases (Table 1).
DISCUSSION
Currently, ADO is a known limitation of PCR-based molecular
diagnostic approaches. Caused by different mechanisms, the
single allele amplifies exclusively or pre-dominantly, leading to
overrepresentation of homozygosity (Wang et al., 2012).
Following the automatization of all molecular diagnostic
procedures—from primer design to variant detection, calling,
and interpretation—that has increased the amount of samples
tested simultaneously, the awareness of ADO events should also
be increased. The Clinical Laboratory Standards Institute (CLSI)
Guidelines recommend that assay development and quality
control should include measures aimed at both detecting allelic
dropout and minimizing its occurrence (CLSI, 2012).
In this study, six ADO events were identified in both
PCR-based sequencing platforms. The causes of these
events were also revealed in all cases. On the IonTorrent
platform, ADO events were caused by rare or unique
genetic variants in the oligoprimer binding sites. On
the capillary sequencing platform, ADO events were
caused by common SNVs in the oligoprimer binding
sites (Table 1). As a result of such selective amplification,
we observed partial hemizygosity or underrepresentation
of the heterozygous genetic variants in the NGS results.
Some of these underrepresented variants may be filtered
automatically during NGS data processing. Cross-validation
of the genetic findings revealed by one sequencing platform
with an alternative approach is a powerful method to decrease
the rate of false-positive results in genetic testing. However,
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FIGURE 2 | Allelic dropout in the SCN5A gene in family with Brugada syndrome. (A) Pedigree of the family; Arrow marks the proband. Het, heterozygous; hem,
hemizygous. (B) Fragment of the Sanger sequencing chromatogram showing the presence of heterozygous variant c.4516C>T in the proband (arrow). (C) Fragment
of the Sanger sequencing chromatogram showing the presence of hemizygous variant c.4516C>T in the II-4 family member (arrow). (D) Control re-sequencing on the
IonTorrent platform showing the family member II-4 is a carrier of heterozygous variant c.4516C>T.
there is no universally-accepted method to decrease—let alone
effectively detect—partial hemizygosity due to allelic dropout.
It seems that resequencing of the region of interest by two
independent oligoprimer pairs remains the “gold standard” of
DNA diagnostics.
There are 2 types of causes of the ADO phenomenon
described in literature (Wang et al., 2012):
(1) “Sample-specific” causes due to the quality of the DNA
sample or the low DNA concentration. Such ADO cases
are found in forensic diagnostics, where only fragmented or
degraded DNA is available, as well as in preimplantation
diagnostics, where genotyping is performed on DNA extracted
from one blastomere;
(2) “Locus-specific” causes due to the characteristics of
the locus under investigation. The presence of single
nucleotide polymorphisms (SNPs) in oligoprimer binding
sites of forward and/or reverse primers disturbs the
specificity of the complementary interaction between the
oligonucleotide and the target DNA sequences, leading to
the lack of oligoprimer hybridization, and elongation of
the amplicon.
All ADO events revealed in this study involved locus-specific
causes due to the characteristics of individual loci in normal
concentrations of DNA.
In cases of locus-specific allelic dropout, the causal SNV in the
oligoprimer binding site is usually located close to the 3′-end of
the oligoprimer. This was initially reported in a study by Martins
et al. (2011). The authors used the rs2247836 variant (MAF
= 0.403 in the European population and 0.323 in the African
population) in the intron 4 of the PAH gene to evaluate the
probability of ADO depending on SNV location in oligoprimer
binding sites. Four alternative variants of forward oligoprimers
were designed containing the SNV in the 3rd, 5th, and 7th
positions of the 3′-end of the oligoprimer. Sanger sequencing
was performed for patients carrying the heterozygous genetic
variant rs2247836 and mutation p.Arg158Gln in exon 5 of the
PAH gene. Loss of heterozygosity was detected for all positions
of the ADO-causing SNV. The authors recommended careful
consideration during primer design of the rare/common SNVs
in areas within 7 nucleotides of the 3′-end of oligoprimers.
We found that the presence of SNVs close to the 5′-end of
oligoprimers may also cause ADO events. Convincing data
suggest that any polymorphic position within the oligoprimer
sequence potentially reduces the accuracy of DNA diagnostics
(Martins et al., 2011).
Data from 30,769 reported genotypes for eight mutations
involved in four diseases show that, on average, allele
dropout/drop-in potentially leading to misdiagnosis occurred in
0.44% of genotype results (Blais et al., 2015).
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TABLE 2 | SNVs localized in the oligoprimers’ binding sites and threatening PCR efficiency.
Gene Amplicon position (hg19) SNV potentially affecting PCR efficiency AF* (gnomAD)
DSP chr6:7574805-7575146 c.2298-85C>T 0.605
DSP chr6:7579369-7580822 c.3085-115C>T 0.676
SCN5A chr3:38622472-38622620 c.3183A>G (p.E1061E) 0.890
LDB3 chr10:88466471-88466552 c.1074C>T (p.A358A) 0.044
LDB3 chr10:88493015-88493177 c.*450G>A 0.001556
FLNC chr7:128480667-128480889 c.1614C>T (p.Y538Y) 0.039
FLNC chr7:128487631-128487861 c.4404T>C (p.D1468D) 0.999
*Allele Frequency in European (non-Finnish) population based on gnomAD data.
We re-analysed the oligoprimer binding sites containing
SNVs within overlapping amplicons and found additional
amplicons that may be missing due to ADO events. The presence
of SNVs in these fragments was exhibited in the NGS reads as
underrepresented variants and/or was revealed in isolated reads
(Table 2).
We hypothesize that the risk of ADO would increase with
the number of target genes and overall panel size because it
would increase number of oligoprimer pairs to cover. Potential
causes of ADO (SNVs) were found in 4 of 521 amplicons in
panel 1 (0.77%). There are increasing numbers of studies that
discuss the importance of ADO in DNA diagnostic procedures
(Tester et al., 2006; Coulet et al., 2010; Medlock et al., 2012;
Rossetti et al., 2012; Lam and Mak, 2013; Shmukler et al.,
2013; Rhees et al., 2014; Blais et al., 2015; Proost, 2016). This
phenomenon was detected in oncogenetics (BRCA1/2 testing),
inborn metabolic disease genotyping (FAH testing), hematology
research etc (Lam and Mak, 2013; Shmukler et al., 2013; Jeong
et al., 2019). We surmise that the actual number of ADO
events remains unknown and may significantly exceed the
events actually detected. The risk of the negative impacts of
possible polymorphic sites in automatically generated primer
sequences on sequencing results remains high. It depends
on the number of overlapping amplicons. It seems that
underrepresentation of genetic variants in NGS reads is not
dependent on the read depth. Jeong et al. demonstrated
a reproducible ADO phenomenon during 3 consecutive re-
sequencing by Ion S5 with read depth from 1985 to 8608 (Jeong
et al., 2019).
Allelic dropout can lead to underdetection of the rare variants
within missing amplicons and increase false negative results rate
in diagnostic setting, and can cause mistaken assignment of
heterozygous genotypes as homozygotes with underestimation
of the observed heterozygosity in population studies. The simple
strategy to restore allelic drop out could be a repeated genotyping
with non-overlapping pairs of oligoprimers. But in daily practice
replicate genotyping is costly. Increasing the tiling density of
amplicons would be also helpful but it requires more oligos for
design and synthesis, and also noticeably increases the assay
price. Another way could be to improve automatic primer design
tools with continuously updating dbSNP and gnomAD data to
omit inclusion of the SNPs into the primer sequences. Analysis
the secondary structure of primer and template sequences would
also be important for the design algorithm (Lam andMak, 2013).
Regular updates on SNV distribution and prevalence in the
human genome and improvement in primer design algorithms
would greatly improve the diagnostic yield of molecular
genetic testing.
In conclusion, PCR-based sequencing technologies such as
next-generation sequencing and Sanger sequencing are widely
used in clinical practice. Despite their high throughput and
constantly improving efficiency, limitations remain for the
application of these technologies.
All PCR-based methods involve the risk that ADO will
decrease the diagnostic yield of genetic testing because of
undetectable, potentially pathogenic variants. We demonstrate
that ADO is a common phenomenon in both NGS and Sanger
sequencing results.
Theoretically, ADO may affect up to 0.77% of amplicons.
It seems that the actual rate of ADO may be even higher
and is dependent on the number of oligoprimer pairs. Specific
software that incorporates updates on the distribution of SNVs to
avoid ADO resulting from automatic oligoprimer design would
substantially increase the accuracy of molecular research.
Oligoprimer sequences are available upon request.
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